Hunting ALK to feed targeted cancer therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21383740.
- Also identified by DOI 10.1038/nm0311-290 and PMC identifier 4344989.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neuroblastoma is a fatal childhood cancer, but lack of knowledge about the underlying causative genes has hampered the development of effective therapies. The identification of anaplastic lymphoma kinase (ALK) mutations as drivers of neuroblastoma has indicated that targeted therapy with ALK inhibitors might be a valuable strategy in the fight against this lethal cancer.
Medical subject headings
- Neuroblastoma
- Protein Kinase Inhibitors
- Protein-Tyrosine Kinases